Biomedical research at Oslo University Hospital

Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.

Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.

Click here to see hierarchical division and subunit overview

Summary of publications:

Publications (original articles or review articles) published in 2020 from OUS - Department of Cancer Immunology

32 publications found

Bai B, Myklebust JH, Wälchli S (2020)
Gene Editing in B-Lymphoma Cell Lines Using CRISPR/Cas9 Technology
Methods Mol Biol, 2115, 445-454
DOI 10.1007/978-1-0716-0290-4_25, PubMed 32006416

Bartolomé-Casado R, Landsverk OJB, Chauhan SK, Sætre F, Hagen KT, Yaqub S, Øyen O, Horneland R, Aandahl EM, Aabakken L, Bækkevold ES, Jahnsen FL (2020)
CD4+ T cells persist for years in the human small intestine and display a TH1 cytokine profile
Mucosal Immunol
DOI 10.1038/s41385-020-0315-5, PubMed 32572129

Caglayan S, Hashim A, Cieslar-Pobuda A, Jensen V, Behringer S, Talug B, Chu DT, Pecquet C, Rogne M, Brech A, Brorson SH, Nagelhus EA, Hannibal L, Boschi A, Taskén K, Staerk J (2020)
Optic Atrophy 1 Controls Human Neuronal Development by Preventing Aberrant Nuclear DNA Methylation
iScience, 23 (6), 101154
DOI 10.1016/j.isci.2020.101154, PubMed 32450518

Casey NP, Kyte JA, Fujiwara H (2020)
Use of RNA Interference with TCR Transfer to Enhance Safety and Efficiency
Methods Mol Biol, 2115, 327-349
DOI 10.1007/978-1-0716-0290-4_18, PubMed 32006409

Cieslar-Pobuda A, Ahrens TD, Caglayan S, Behringer S, Hannibal L, Staerk J (2020)
DNMT3B deficiency alters mitochondrial biogenesis and α-ketoglutarate levels in human embryonic stem cells
Stem Cells
DOI 10.1002/stem.3256, PubMed 32652733

Clement D, Goodridge JP, Grimm C, Patel S, Malmberg KJ (2020)
TRP Channels as Interior Designers: Remodeling the Endolysosomal Compartment in Natural Killer Cells
Front Immunol, 11, 753
DOI 10.3389/fimmu.2020.00753, PubMed 32411146

Darvekar S, Juzenas P, Oksvold M, Kleinauskas A, Holien T, Christensen E, Stokke T, Sioud M, Peng Q (2020)
Selective Killing of Activated T Cells by 5-Aminolevulinic Acid Mediated Photodynamic Effect: Potential Improvement of Extracorporeal Photopheresis
Cancers (Basel), 12 (2)
DOI 10.3390/cancers12020377, PubMed 32041351

Evers M, Ten Broeke T, Jansen JHM, Nederend M, Hamdan F, Reiding KR, Meyer S, Moerer P, Brinkman I, Rösner T, Lebbink RJ, Valerius T, Leusen JHW (2020)
Novel chimerized IgA CD20 antibodies: Improving neutrophil activation against CD20-positive malignancies
MAbs, 12 (1), 1795505
DOI 10.1080/19420862.2020.1795505, PubMed 32744145

Iversen PO, Sioud M (2020)
Harnessing the Antiviral-Type Responses Induced by Immunostimulatory siRNAs for Cancer Immunotherapy
Methods Mol Biol, 2115, 281-287
DOI 10.1007/978-1-0716-0290-4_16, PubMed 32006407

Jakobsen LH, Ellin F, Smeland KB, Wästerlid T, Christensen JH, Jørgensen JM, Josefsson PL, Øvlisen AK, Holte H, Blaker YN, Grauslund JH, Bjørn J, Molin D, Lagerlöf I, Smedby KE, Colvin K, Thanarajasingam G, Maurer MJ, Habermann TM, Song KW, Zhu KY, Gerrie AS, Cheah CY, El-Galaly TC (2020)
Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients
Br J Haematol, 189 (4), 661-671
DOI 10.1111/bjh.16425, PubMed 32017050

Kuttner S, Wickstrom KK, Kalda G, Dorraji SE, Martin-Armas M, Oteiza A, Jenssen R, Fenton K, Sundset R, Axelsson J (2020)
Machine learning derived input-function in a dynamic F-18-FDG PET study of mice
Biomed. Phys. Eng. Express, 6 (1), 015020

Kyte JA, Andresen NK, Russnes HG, Fretland SØ, Falk RS, Lingjærde OC, Naume B (2020)
ICON: a randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer
J Transl Med, 18 (1), 269
DOI 10.1186/s12967-020-02421-w, PubMed 32620163

Kyte JA, Røssevold A, Falk RS, Naume B (2020)
ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer
J Transl Med, 18 (1), 252
DOI 10.1186/s12967-020-02424-7, PubMed 32576225

Majzner RG, Rietberg SP, Sotillo E, Dong R, Vachharajani VT, Labanieh L, Myklebust JH, Kadapakkam M, Weber EW, Tousley AM, Richards RM, Heitzeneder S, Nguyen SM, Wiebking V, Theruvath J, Lynn RC, Xu P, Dunn AR, Vale RD, Mackall CL (2020)
Tuning the Antigen Density Requirement for CAR T-cell Activity
Cancer Discov, 10 (5), 702-723
DOI 10.1158/2159-8290.CD-19-0945, PubMed 32193224

Mato AR, Roeker LE, Lamanna N, Allan JN, Leslie L, Pagel JM, Patel K, Osterborg A, Wojenski D, Kamdar M, Huntington SF, Davids MS, Brown JR, Antic D, Jacobs R, Ahn IE, Pu J, Isaac KM, Barr PM, Ujjani CS, Geyer MB, Berman E, Zelenetz AD, Malakhov N, Furman RR et al. (2020)
Outcomes of COVID-19 in patients with CLL: a multicenter international experience
Blood, 136 (10), 1134-1143
DOI 10.1182/blood.2020006965, PubMed 32688395

Maucourant C, Filipovic I, Ponzetta A, Aleman S, Cornillet M, Hertwig L, Strunz B, Lentini A, Reinius B, Brownlie D, Cuapio A, Ask EH, Hull RM, Haroun-Izquierdo A, Schaffer M, Klingström J, Folkesson E, Buggert M, Sandberg JK, Eriksson LI, Rooyackers O, Ljunggren HG, Malmberg KJ, Michaëlsson J, Marquardt N et al. (2020)
Natural killer cell immunotypes related to COVID-19 disease severity
Sci Immunol, 5 (50)
DOI 10.1126/sciimmunol.abd6832, PubMed 32826343

Meås HZ, Haug M, Beckwith MS, Louet C, Ryan L, Hu Z, Landskron J, Nordbø SA, Taskén K, Yin H, Damås JK, Flo TH (2020)
Sensing of HIV-1 by TLR8 activates human T cells and reverses latency
Nat Commun, 11 (1), 147
DOI 10.1038/s41467-019-13837-4, PubMed 31919342

Mobergslien A, Sioud M (2020)
Exploring 5'-Biotinylation of the Sense Strand to Improve siRNA Specificity and Potency
Methods Mol Biol, 2115, 163-170
DOI 10.1007/978-1-0716-0290-4_9, PubMed 32006400

Pfefferle A, Jacobs B, Haroun-Izquierdo A, Kveberg L, Sohlberg E, Malmberg KJ (2020)
Deciphering Natural Killer Cell Homeostasis
Front Immunol, 11, 812
DOI 10.3389/fimmu.2020.00812, PubMed 32477340

Radzikowska U, Ding M, Tan G, Zhakparov D, Peng Y, Wawrzyniak P, Wang M, Li S, Morita H, Altunbulakli C, Reiger M, Neumann AU, Lunjani N, Traidl-Hoffmann C, Nadeau KC, O'Mahony L, Akdis C, Sokolowska M (2020)
Distribution of ACE2, CD147, CD26, and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors
Allergy
DOI 10.1111/all.14429, PubMed 32496587

Rein ID, Notø HØ, Bostad M, Huse K, Stokke T (2020)
Cell Cycle Analysis and Relevance for Single-Cell Gating in Mass Cytometry
Cytometry A, 97 (8), 832-844
DOI 10.1002/cyto.a.23960, PubMed 31943748

Sioud M (2020)
Microbial sensing by hematopoietic stem and progenitor cells: Vigilance against infections and immune education of myeloid cells
Scand J Immunol, e12957 (in press)
DOI 10.1111/sji.12957, PubMed 32767789

Sioud M (2020)
RNA and CRISPR Interferences: Past, Present, and Future Perspectives
Methods Mol Biol, 2115, 1-22
DOI 10.1007/978-1-0716-0290-4_1, PubMed 32006392

Sioud M (2020)
Unleashing the Therapeutic Potential of Dendritic and T Cell Therapies Using RNA Interference
Methods Mol Biol, 2115, 259-280
DOI 10.1007/978-1-0716-0290-4_15, PubMed 32006406

Sioud M (2020)
Optimized siRNA Delivery into Primary Immune Cells Using Electroporation
Methods Mol Biol, 2115, 119-131
DOI 10.1007/978-1-0716-0290-4_7, PubMed 32006398

Skånland SS, Karlsen L, Taskén K (2020)
B cell signaling pathways - new targets for precision medicine in CLL
Scand J Immunol, e12931 (in press)
DOI 10.1111/sji.12931, PubMed 32640099

Sonnet F, Namork E, Stylianou E, Gaare-Olstad I, Huse K, Andorf S, Mjaaland S, Dirven H, Nygaard U (2020)
Reduced polyfunctional T cells and increased cellular activation markers in adult allergy patients reporting adverse reactions to food
BMC Immunol, 21 (1), 43
DOI 10.1186/s12865-020-00373-w, PubMed 32698761

Sæbøe-Larssen S, Sioud M (2020)
Improving Dendritic Cell Cancer Vaccine Potency Using RNA Interference
Methods Mol Biol, 2115, 249-258
DOI 10.1007/978-1-0716-0290-4_14, PubMed 32006405

Winge-Main AK, Wälchli S, Inderberg EM (2020)
T cell receptor therapy against melanoma-Immunotherapy for the future?
Scand J Immunol, 92 (4), e12927
DOI 10.1111/sji.12927, PubMed 32640053

Wise JF, Nakken S, Steen CB, Vodák D, Trøen G, Johannessen B, Lingjærde OC, Hilden V, Blaker YN, Bai B, Aasheim LB, Pasanen A, Lorenz S, Sveen A, Lothe RA, Myklebost O, Leppä S, Meza-Zepeda LA, Beiske K, Lawrence MS, Hovig E, Myklebust JH, Smeland EB, Holte H (2020)
Mutational dynamics and immune evasion in diffuse large B-cell lymphoma explored in a relapse-enriched patient series
Blood Adv, 4 (9), 1859-1866
DOI 10.1182/bloodadvances.2019001325, PubMed 32374878

Wälchli S, Sioud M (2020)
Next Generation of Adoptive T Cell Therapy Using CRISPR/Cas9 Technology: Universal or Boosted?
Methods Mol Biol, 2115, 407-417
DOI 10.1007/978-1-0716-0290-4_22, PubMed 32006413

Zhu H, Blum RH, Bernareggi D, Ask EH, Wu Z, Hoel HJ, Meng Z, Wu C, Guan KL, Malmberg KJ, Kaufman DS (2020)
Metabolic Reprograming via Deletion of CISH in Human iPSC-Derived NK Cells Promotes In Vivo Persistence and Enhances Anti-tumor Activity
Cell Stem Cell, 27 (2), 224-237.e6
DOI 10.1016/j.stem.2020.05.008, PubMed 32531207

 
Page visits: 442351